Capabilities

Agreement with Vanda Pharmaceuticals

Novartis

Our attorneys represented Novartis in an agreement with Vanda Pharmaceuticals Inc. for exclusive US and Canadian rights to Fanapt™ (iloperidone), a new oral medication that is approved by the US Food and Drug Administration (FDA) for the acute treatment of adults with schizophrenia.

Email Disclaimer